One of the first investigations of lncRNAs in NAFLD fibrosis demonstrated that MEG3 expression was decreased in livers from CCl4-treated mice, when compared to oil-fed control animals, and that Meg3 expression diminished concordantly with progression of fibrosis [61]. The gene discussed is MEG3; the disease is metabolic dysfunction-associated steatotic liver disease.